Skip to content

NASDAQ · large · thesis board

ALNY Alnylam Pharmaceuticals

RNAi therapeutics platform

View race

Thesis

Editorial summary — not a primary filing

RNAi commercial engine funding next TTR and rare programs.

Next gate

2026-09-10Company-guidedlabel expand

TTR franchise update

28 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~26 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~811d)100%
Days to gate (28d)3%
Show math

$2.4B cash ÷ $90M/mo burn ≈ 811 days. Source: curated SEC quarter figures.

Cash $2.4B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
NTLAPh3okCRSPPh1okBEAMPh1ok

Risks

  • Competitive TTR space
  • Pricing
  • Pipeline expansion
  • Execution

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT04153149as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01